Clinical trials
Phase 1 Neuromyelitis Optica trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2018 | 1 |
| 2020 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 6 |
| Completed | 4 |
| Not yet recruiting | 4 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tongji Hospital | 3 |
| Chinese PLA General Hospital | 2 |
| Tianjin Huanhu Hospital | 2 |
| Bio-Thera Solutions | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| Harbour BioMed (Guangzhou) Co. Ltd. | 1 |
| Nanjing Bioheng Biotech Co., Ltd. | 1 |
| RenJi Hospital | 1 |
| Shanghai Pharmaceuticals Holding Co., Ltd | 1 |
| The Affiliated Hospital of Qingdao University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuromyelitis Optica | 17 |
| Multiple Sclerosis | 8 |
| Myasthenia Gravis | 7 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 4 |
| Autoimmune Diseases of the Nervous System | 3 |
| Lupus Erythematosus, Systemic | 2 |
| Myositis | 2 |
| Scleroderma, Systemic | 2 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 |
| Autoimmune Diseases | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.